{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=52",
    "query": {
      "condition": "Lymphoid",
      "page": 52
    },
    "page_size": 10
  },
  "pagination": {
    "page": 52,
    "page_size": 10,
    "total_count": 3083,
    "total_pages": 309,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=53&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoid&page=51&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T20:52:44.036Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01671904",
      "title": "A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2014-01-13",
      "completion_date": "2020-08-11",
      "has_results": false,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 4,
      "location_summary": "La Jolla, California • Harvey, Illinois • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Yakima",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01671904"
    },
    {
      "nct_id": "NCT00101595",
      "title": "Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Myeloid Leukemia",
        "Leukemia, Lymphoblastic, Acute, Philadelphia-positive"
      ],
      "interventions": [
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 96,
      "start_date": "2005-01",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2011-04-14",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Los Angeles, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00101595"
    },
    {
      "nct_id": "NCT00003956",
      "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "lonafarnib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "1999-04",
      "completion_date": "2009-12",
      "has_results": false,
      "last_update_posted_date": "2013-04-04",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003956"
    },
    {
      "nct_id": "NCT00005802",
      "title": "Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "therapeutic hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1999-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005802"
    },
    {
      "nct_id": "NCT02225275",
      "title": "Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2016-03-31",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-09-28",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02225275"
    },
    {
      "nct_id": "NCT04494945",
      "title": "Identifying and Caring for Individuals With Inherited Cancer Syndrome",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome",
        "Breast Ductal Carcinoma In Situ",
        "Hematopoietic and Lymphoid System Neoplasm",
        "Hereditary Neoplastic Syndrome",
        "Lynch Syndrome",
        "Malignant Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Genetic Counseling",
          "type": "OTHER"
        },
        {
          "name": "Genetic Testing",
          "type": "OTHER"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "OHSU Knight Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27500,
      "start_date": "2020-03-09",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 2,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04494945"
    },
    {
      "nct_id": "NCT07638722",
      "title": "Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With Treatment",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Recurrent Nodal Marginal Zone Lymphoma",
        "Recurrent Splenic Marginal Zone Lymphoma",
        "Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
        "Refractory Nodal Marginal Zone Lymphoma",
        "Refractory Splenic Marginal Zone Lymphoma"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Mosunetuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Polatuzumab Vedotin",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Zanubrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2026-10-03",
      "completion_date": "2035-04-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 14,
      "location_summary": "Newark, Delaware • Coeur d'Alene, Idaho • Post Falls, Idaho + 10 more",
      "locations": [
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        },
        {
          "city": "Post Falls",
          "state": "Idaho"
        },
        {
          "city": "Sandpoint",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07638722"
    },
    {
      "nct_id": "NCT03056339",
      "title": "Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "B-Lymphoid Malignancies",
        "Acute Lymphocytic Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Non-hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Mesna",
          "type": "DRUG"
        },
        {
          "name": "iC9/CAR.19/IL15-Transduced CB-NK Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AP1903",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "7 Years to 80 Years"
      },
      "enrollment_count": 49,
      "start_date": "2017-06-21",
      "completion_date": "2023-03-06",
      "has_results": true,
      "last_update_posted_date": "2024-03-25",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03056339"
    },
    {
      "nct_id": "NCT01427881",
      "title": "Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Erythroleukemia (M6a)",
        "Adult Nasal Type Extranodal NK/T-cell Lymphoma",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Anaplastic Large Cell Lymphoma",
        "Angioimmunoblastic T-cell Lymphoma",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Childhood Acute Erythroleukemia (M6)",
        "Childhood Acute Lymphoblastic Leukemia in Remission",
        "Childhood Acute Megakaryocytic Leukemia (M7)",
        "Childhood Acute Myeloid Leukemia in Remission",
        "Childhood Burkitt Lymphoma",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Childhood Myelodysplastic Syndromes",
        "Childhood Nasal Type Extranodal NK/T-cell Lymphoma",
        "Chronic Myelomonocytic Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "Cutaneous B-cell Non-Hodgkin Lymphoma",
        "de Novo Myelodysplastic Syndromes",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Hepatosplenic T-cell Lymphoma",
        "Intraocular Lymphoma",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncutaneous Extranodal Lymphoma",
        "Peripheral T-cell Lymphoma",
        "Philadelphia Chromosome Negative Chronic Myelogenous Leukemia",
        "Post-transplant Lymphoproliferative Disorder",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Grade III Lymphomatoid Granulomatosis",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Adult T-cell Leukemia/Lymphoma",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Anaplastic Large Cell Lymphoma",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Small Intestine Lymphoma",
        "Splenic Marginal Zone Lymphoma",
        "Stage III Multiple Myeloma",
        "Testicular Lymphoma",
        "Waldenström Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "busulfan",
          "type": "DRUG"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "Up to 65 Years"
      },
      "enrollment_count": 43,
      "start_date": "2011-09",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2017-05-19",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01427881"
    },
    {
      "nct_id": "NCT02360930",
      "title": "Vincristine PK and PD in the AYA Population Compared to Younger Children",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leukemia, Acute Lymphoblastic",
        "Leukemia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Children's Hospital Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "1 Year to 24 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-09",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2015-06-22",
      "last_synced_at": "2026-11-12T20:52:44.036Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02360930"
    }
  ]
}